Viibryd (Vilazodone): Viable option or for the byrds?

Vilazodone was approved by the Food and Drug Administration (FDA) in January of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

Download Full-text

Saphris: Does a unique delivery system equal a unique drug?

Mental Health Clinician ◽

10.9740/mhc.n89388 ◽

2011 ◽

Vol 1 (6) ◽

pp. 133-134

Author(s):

Kelly N. Gable

Keyword(s):

Clinical Trial ◽

Adverse Effects ◽

Drug Interactions ◽

Drug Administration ◽

Delivery System ◽

Mechanism Of Action ◽

Food And Drug Administration ◽

Clinical Trial Evidence ◽

Clinically Significant ◽

Trial Evidence

Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

Download Full-text

Iloperidone (Fanapt®): Fan or not?

Mental Health Clinician ◽

10.9740/mhc.n89390 ◽

2011 ◽

Vol 1 (6) ◽

pp. 137-139

Author(s):

Uma Newton ◽

Tiffany-Jade Kreys

Keyword(s):

Clinical Trial ◽

Adverse Effects ◽

Drug Interactions ◽

Drug Administration ◽

Mechanism Of Action ◽

Food And Drug Administration ◽

New Drug ◽

Clinical Trial Evidence ◽

Clinically Significant ◽

Trial Evidence

Iloperidone was approved by the Food and Drug Administration (FDA) in May of 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

Download Full-text

New Drug Review-Ezogabine (Potiga): Seizing the seizure

Mental Health Clinician ◽

10.9740/mhc.n89803 ◽

2011 ◽

Vol 1 (6) ◽

pp. 135-136

Author(s):

Misty L. Gonzalez

Keyword(s):

Clinical Trial ◽

Adverse Effects ◽

Drug Interactions ◽

Drug Administration ◽

Mechanism Of Action ◽

New Drug ◽

Clinical Trial Evidence ◽

Clinically Significant ◽

Trial Evidence ◽

Drug Review

Ezogabine was approved by the Food and Drug Administration (FDA) in June of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

Download Full-text

New Drug Review: Clobazam (Onfi®) - A “new” anticonvulsant option

Mental Health Clinician ◽

10.9740/mhc.n89385 ◽

2011 ◽

Vol 1 (6) ◽

pp. 126-127

Author(s):

Jamie Holmes ◽

Robin Hieber

Keyword(s):

Clinical Trial ◽

Adverse Effects ◽

Drug Interactions ◽

Drug Administration ◽

Mechanism Of Action ◽

New Drug ◽

Clinical Trial Evidence ◽

Clinically Significant ◽

Trial Evidence ◽

Drug Review

Clobazam was approved by the Food and Drug Administration (FDA) in October of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

Download Full-text

New Drug Review: Lurasidone (Latuda®) - The new antipsychotic on the block

Mental Health Clinician ◽

10.9740/mhc.n89387 ◽

2011 ◽

Vol 1 (6) ◽

pp. 131-132 ◽

Cited By ~ 1

Author(s):

Kelly N. Gable

Keyword(s):

Clinical Trial ◽

Adverse Effects ◽

Drug Interactions ◽

Drug Administration ◽

Mechanism Of Action ◽

New Drug ◽

Clinical Trial Evidence ◽

Clinically Significant ◽

Trial Evidence ◽

Drug Review

Lurasidone was approved by the Food and Drug Administration (FDA) in 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

Download Full-text

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

JAMA Network Open ◽

10.1001/jamanetworkopen.2020.24406 ◽

2020 ◽

Vol 3 (11) ◽

pp. e2024406

Author(s):

Aviv Ladanie ◽

Andreas M. Schmitt ◽

Benjamin Speich ◽

Florian Naudet ◽

Arnav Agarwal ◽

...

Keyword(s):

Clinical Trial ◽

Drug Administration ◽

Food And Drug Administration ◽

Cancer Therapies ◽

Clinical Trial Evidence ◽

Trial Evidence

Download Full-text

New Drug Review: Gabapentin enacarbil extended release (Horizant™) – A new formulation on the horizon

Mental Health Clinician ◽

10.9740/mhc.n89391 ◽

2011 ◽

Vol 1 (6) ◽

pp. 128-130

Author(s):

Amy B. Werremeyer

Keyword(s):

Clinical Trial ◽

Adverse Effects ◽

Extended Release ◽

Gabapentin Enacarbil ◽

New Drug ◽

Clinical Trial Evidence ◽

Clinically Significant ◽

New Formulation ◽

Trial Evidence ◽

Drug Review

Gabapentin enacarbil was approved by the Food and Drug Administration (FDA) in April of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

Download Full-text